[1]Papac RJ.Origins of cancer therapy[J].Yale J Biol Med,2001,74(6):391-398.
[2]Schrama D,Becker JC,Reisfeld RA.Antibody targeted drugs ascancer therapeutics[J].Nat Rev Drug Dis,2006,5:147-159.
[3]陈其,钱其军,达万明.用于血液系统恶性肿瘤治疗的单克隆抗体[J].白血病·淋巴瘤,2005,5:248-251.
[4]Litman GW,Rast JP,Shamblott MJ,et al.Phylogenetic diversifi-cation of immunoglobulin genes and the antibody repertoire[J].Mol Biol Evol,1993,10(1):60-72.
[5]刘萍,陈苗苗,刘学荣,等.单克隆抗体研究进展[J].中国畜牧兽医,2012,39(1):67-70.
[6]Cobleigh MA,Vogel CL,Tripathy D,et al.Multinational study ofthe efficacy and safety of humanized anti-HER2 monoclonalantibody in women who have HER2-overexpressing metastaticbreast cancer that has progressed after chemotherapy for metastaticdisease[J].J Clin Oncol,1999,17(9):2639-2648.
[7]Johnson JR,Ford CH,Newman CE,et al.A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro[J].Br JCancer,1981,44(3):472-475.
[8]Garnett MC.Targeted drug conjugates:Principles and progress[J].Adv Drug Deliv Rev,2001,53(2):171-216.
[9]Maxfield FR,Mcgraw TE.Endocytic recycling[J].Nature RevMol Cell Biol,2004,5:121-132.
[10]Singh R,Erickson HK.Antibody-cytotoxic agent conjugates:Preparation and characterization[J].Methods Mol Biol,2009,525(4):445-467.
[11]Jaracz S,Chen J,Kuznetsova LV,et al.Recent advances intumor-targeting anticancer drug conjugates[J].Bioorg MedChem,2005,13(17):5043-5044.
[12]Kelly RK,Olson DL,Sun YP,et al.An antibody-cytotoxic con-jugate,BIIB015,is a new targeted therapy for Cripto positivetumours[J].Eur J Cancer,2011,7(11):1736-1746.
[13]Choi E,SUN C,Garber E,et al.CRIPTO3,a presumed pseudo-gene is expressed in cancer[J].Biochem Biophys Res Commun,2008,377(1):215-220.
[14]Lorusso PM,Weiss D,Guardino E,et al.Trastuzumab emtansine:A unique antibody-drug conjugate in development for human ep-idermal growth factor receptor 2-positive cancer[J].Clin CancerRes,2011,17(20):6437-6447.
[15]邢爱敏.用于治疗乳腺癌的抗体-药物共轭物TrastuzumabEmtansine[J].药学进展,2012,36(6):284-285.
[16]Al-Katib AM,Aboukameel A,Mohammad R,et al.Superiorantitumor activity of SAR3419 to rituximab in xenograft models fornon-Hodgkin’s lymphoma[J].Clin Cancer Res,2009,15(12):4038-4045.
[17]Polson AG,Williams M,Gray AM,et al.Anti-CD22-MCC-DM1:An antibody-drug conjugate with a stable linker for thetreatment of non-Hodgkin's lymphoma[J].Leukemia,2010,24:1566-1573.
[18]Zhao RY,Wilhelm SD,Audette C,et al.Synthesis and evaluationof hydrophilic linkers for antibody maytansinoid conjugates[J].JMed Chem,2011,54(10):3606-3623.
[19]Jona A,Younes A.Novel treatment strategies for patients with re-lapsed classical Hodgkin lymphoma[J].Blood Rev,2010,24(6):233-238.
[20]Fanale M,Franklin A,Radhakrishnan R,et al.9201 ORAL com-plete remissions observed in a subset of pediatric patients withCD30-expressing malignant lymphomas treated in clinical stud-ies of brentuximab vedotin(SGN-35)[Z].Oral PresentationsHaematological Malignancies,2011,47(1):s640.
[21]Alley SC,Okeley NM,Senter PD.Antibody-drug conjugates:Targeted drug delivery for cancer[J].Curr Opin Chem Biol,2010,14(4):529-537.
[22]Stasi R,Evangelista ML,Buccisano F,et al.Gemtuzumab ozogam-icin in the treatment of acute myeloid leukemia[J].Cancer TreatRev,2008,34(1):49-60.
[23]Biedermann B,Gil D,Bowen DT,et al.Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic recep-tor expressed on subsets of acute myeloid leukemia cells and ab-sent from normal hematopoietic progenitors[J].Leuk Res,2007,31(2):211-220.
[24]Elmroth K,Nygren J,Mrtensson S,et al.Cleavage of cellularDNA by calicheamicinγ1[J].DNA Repair,2003,2(4):363-374.
[25]Fayad L,Patel H,Verhoef G,et al.Safety and clinical activity ofthe anti-CD22 immunoconjugate inotuzumab ozogamicin(CMC-544)in combination with rituximab in follicular lympho-ma or diffuse large B-cell lymphoma:preliminary report of aphase 1/2 study[Z].Blood(ASH Annual Meeting Abstracts),2008,112(11):266.
[26]Dubowchik GM,Walker MA.Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs[J].Pharmacolo-gy Ther,1999,83(2):67-123.
[27]Emons G,Günthert AR,Gründker C,et al.Dose escalation andpharmacokinetic study of AEZS-108(AN-152),an LHRH ag-onist linked to doxorubicin,in women with LHRH receptor-posi-tive tumors[J].Gynecol Oncol,2010,119(3):457-461.
[28]Zhao RY,Erickson HK,Leece BA,et al.Synthesis and biologicalevaluation of antibody conjugates of phosphate prodrugs of cyto-toxic DNA alkylators for the targeted treatment of cancer[J].JMed Chem,2012,55(2):766-782.
[29]Boger DL,Boyce CW,Garbaccio RM,et al.CC-1065 and theduocarmycins:Synthetic studies[J].Chem Rev,1997,97(3):787-828.
[30]Sapra P,Hooper AT,O'Donnell CJ,et al.Investigational antibodydrug conjugates for solid tumors[J].Expert Opin Investig Drugs,2011,20(8):1131-1149.
[31]Mandler R,Dadachova E,Brechbiel JK,et al.Synthesis and eval-uation of antiproliferative activity of a geldanamycin±Hercep-tinTM immunoconjugate[J].Bioorg Med Chem Lett,2000,10(10):1025-1028.
[32]Burke PJ,Toki BE,Meyer DW,et al.Novel Immunoconjugatescomprised of streptonigrin and 17-amino-geldanamycin atta-ched via a dipeptide-p-aminobenzyl-amine linker system[J].Bioorg Med Chem Lett,2009,19(10):2650-2653.
[33]Orcutt KD,Slusarczyk AL,Yi BR,et al.Engineering an antibodywith picomolar affinity to DOTA chelates of multiple radionuclidesfor pretargeted radioimmunotherapy and imaging[J].Nucl MedBiol,2011,38(2):223-233.
[34]Mohsin H,Fitzsimmons J,Jurisson SS,et al.Preparation and bio-logical evaluation of 111In,177Lu-and90Y-labeledDOTAana-logues conjugated to B72.3[J].Nucl Med Biol,2007,34(5):493-502.
[35]Hens M,Vaidyanathan G,Welsh P,et al.Labeling internalizinganti-epidermal growth factor receptor variantⅢmonoclonal an-tibody with177Lu:In vitro comparison of acyclic and macrocyclicligands[J].Nucl Med Biol,2009,36(2):117-128.
[36]Yousefnia H,Radfar E,Jalilian AR,et al.Development of177Lu-DOTA-anti-CD20 for radioimmunotherapy[J].Radioanal NuclChem,2011,287:199-209.
[37]Heyerdahl H,Abbas N,Brevik EM,et al.Fractionated therapyofHER2-Expressing breast and ovarian cancer xenografts in micewith targeted alpha emitting227Th-DOTA-p-benzyl-trastu-zumab[J].PLos One,2012,7(8):e42345.
[38]Kang CS,Sun X,Jia F,et al.Synthesis and preclinical evaluationof bifunctional ligands for improved chelation chemistry of90Yand177Lu for targeted radioimmunotherapy[J].Bioconjug Chem,2012,23(9):1775-1782.
[39]陈立波,朱瑞森.Bexxar治疗非霍奇金淋巴瘤的研究现状[J].国外医学·放射医学核医学分册,2005,29(2):67-70.
[40]Stille AB,Boerman OC,Desar IM,et al.Phase 1 radioimmuno-therapy study with lutetium177-labeled anti-carbonic anhy-draseⅨmonoclonal antibody girentuximab in patients withadvanced renal cell carcinoma[J].Eur Urol,2012,8:4702.
[41]Zalutsky MR,Pozzi OR,Vaidyanathan G,et al.Targeted a-parti-cle radiotherapy with211At-labeled monoclonal antibodies[J].Nucl Med Biol,2007,34(7):779-785.
[42]Decker MD,Vos FD,Bacher K,et al.In vitro and in vivo evalua-tion of direct rhenium-188-labeled anti-CD52 monoclonalantibody alemtuzumab for radioimmunotherapy of B-cell chroniclymphocytic leukemia[J].Nucl Med Biol,2008,35(5):599-604.
[43]Mattijssen V,De mulder PH,Joosten F,et al.Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrenthead and neck squamous-cell carcinoma[J].Ann Oncol,1995,5(10):957-960.
[44]Ou XH,Tan TZ,He L,et al.Antitumor effects of radioiodinatedantisense oligonuclide mediated by VIP receptor[J].Cancer GeneTher,2005,12:313-320.
[45]Afshar S,Asai T,Morrison SL.Humanized ADEPT comprised ofan engineered human purine nucleoside phosphorylase and atumor targeting peptide for treatment of cancer[J].Mol CancerTher,2009,8(1):185-193.
[46]Kamal A,Rao MV,Laxman N,et al.Recent developments in thedesign,synthesis and structure-activity relationship studies ofpyrrolo[2,1-c][1,4]benzodiazepines as DNA-interactive an-titumour antibiotics[J].Curr Med Chem Anticancer Agents,2002,2(2):215-254.
